EVENITY
EVENITY is a fast-acting, high-efficacy treatment for severe osteoporosis in postmenopausal women. With measurable fracture risk reduction and BMD improvements in just 12 months, it’s an effective frontline or rescue therapy when other agents fail. For practices focused on outcomes, EVENITY offers both speed and durability—with results that continue after transition to standard antiresorptives. Contact Doctor Medica’s customer service representatives for guidance on how to order Evenity online.
Find More with Just a Click!
Can’t spot what you need in our catalog? Fret not–just sign up for our expert consultations. We will provide the insights you need. We're here to guide you to your clinic's potential; no product browsing needed
No products were found matching your selection.
EVENITY at a Glance
EVENITY® is a once-monthly injectable treatment for postmenopausal osteoporosis at high fracture risk. It works by inhibiting sclerostin, increasing bone formation and reducing resorption.
- Dose: 210 mg SC, given as two 105 mg injections once monthly
- Use limit: 12 doses (1 year max)
- Mechanism: Dual-action—bone formation + anti-resorption
Performance Benefits for Clinical Use
EVENITY delivers rapid BMD increases and reduces fracture risk across high-risk patient populations.
- 73% relative reduction in new vertebral fractures at 12 months
- 75% reduction in vertebral fractures at 24 months with follow-up antiresorptive use
- 13% increase in lumbar spine BMD at 12 months
- 8.1% lumbar spine BMD gain sustained at 24 months with sequential alendronate
- Outperforms alendronate in BMD gains and fracture prevention
Ideal EVENITY Use Cases and Patient Profiles
Indicated for postmenopausal women with osteoporosis at high risk for fracture—especially those who:
- Have a prior osteoporotic fracture
- Have multiple fracture risk factors
- Are intolerant or unresponsive to other osteoporosis treatments
Note: Not for patients with MI or stroke in the past year
EVENITY Core Ingredients and Their Roles
Each prefilled syringe contains romosozumab-aqqg, a humanized monoclonal antibody.
- Active: Romosozumab-aqqg 105 mg/1.17 mL
- Excipients: Sucrose, calcium, acetate, polysorbate 20, sodium hydroxide, water for injection
- pH adjusted to 5.2
EVENITY Injection Techniques and Application Guide
EVENITY must be administered by a healthcare professional. Each monthly dose requires two injections.
- Dose: 210 mg SC monthly, via two 105 mg prefilled syringes
- Sites: Abdomen, thigh, or upper arm
- Rotate injection sites; avoid irritated or scarred skin
- Missed dose: Reschedule promptly; resume monthly from new date
- Supplement with calcium and vitamin D throughout treatment
EVENITY Storage, Shelf Life, and Handling
Proper storage is critical for drug stability and efficacy.
- Refrigerate at 2–8°C (36–46°F) in original carton
- Do not freeze or shake
- At room temp (max 25°C/77°F): stable for up to 30 days
- Inspect prior to use: solution should be clear to light yellow, free of particles
EVENITY Side Effects: What to Monitor
Monitor patients for both common and serious events.
Common (≥5%):
- Arthralgia
- Headache
Serious:
- Cardiovascular: MI, stroke, cardiovascular death—hazard ratio 1.87 vs alendronate
- Hypocalcemia: Especially in renal impairment; correct before starting
- ONJ and atypical femoral fractures: Evaluate dental health and thigh/groin pain
- Hypersensitivity: Angioedema, rash, urticaria—discontinue if reaction occurs
Key Practitioner Questions About EVENITY Answered
How long can EVENITY be used?
- 12 months max. Afterward, transition to an antiresorptive agent.
Is it effective alone?
- Yes, but follow-up with denosumab or alendronate sustains BMD gains.
Can patients self-inject?
- No. Must be administered by a licensed provider.
Is it safe in renal impairment?
- No dose adjustment needed, but monitor calcium in severe impairment or dialysis.
What happens after stopping?
- Without follow-up treatment, BMD returns to baseline within 12 months
How to Order EVENITY for Your Practice
EVENITY is a prescription biologic available via licensed distributors for in-clinic administration.
Contact Doctor Medica’s customer service representatives for guidance on how to order Evenity online.
Other information
EVENITY at a Glance
EVENITY® is a once-monthly injectable treatment for postmenopausal osteoporosis at high fracture risk. It works by inhibiting sclerostin, increasing bone formation and reducing resorption.
- Dose: 210 mg SC, given as two 105 mg injections once monthly
- Use limit: 12 doses (1 year max)
- Mechanism: Dual-action—bone formation + anti-resorption
Performance Benefits for Clinical Use
EVENITY delivers rapid BMD increases and reduces fracture risk across high-risk patient populations.
- 73% relative reduction in new vertebral fractures at 12 months
- 75% reduction in vertebral fractures at 24 months with follow-up antiresorptive use
- 13% increase in lumbar spine BMD at 12 months
- 8.1% lumbar spine BMD gain sustained at 24 months with sequential alendronate
- Outperforms alendronate in BMD gains and fracture prevention
Ideal EVENITY Use Cases and Patient Profiles
Indicated for postmenopausal women with osteoporosis at high risk for fracture—especially those who:
- Have a prior osteoporotic fracture
- Have multiple fracture risk factors
- Are intolerant or unresponsive to other osteoporosis treatments
Note: Not for patients with MI or stroke in the past year
EVENITY Core Ingredients and Their Roles
Each prefilled syringe contains romosozumab-aqqg, a humanized monoclonal antibody.
- Active: Romosozumab-aqqg 105 mg/1.17 mL
- Excipients: Sucrose, calcium, acetate, polysorbate 20, sodium hydroxide, water for injection
- pH adjusted to 5.2
EVENITY Injection Techniques and Application Guide
EVENITY must be administered by a healthcare professional. Each monthly dose requires two injections.
- Dose: 210 mg SC monthly, via two 105 mg prefilled syringes
- Sites: Abdomen, thigh, or upper arm
- Rotate injection sites; avoid irritated or scarred skin
- Missed dose: Reschedule promptly; resume monthly from new date
- Supplement with calcium and vitamin D throughout treatment
EVENITY Storage, Shelf Life, and Handling
Proper storage is critical for drug stability and efficacy.
- Refrigerate at 2–8°C (36–46°F) in original carton
- Do not freeze or shake
- At room temp (max 25°C/77°F): stable for up to 30 days
- Inspect prior to use: solution should be clear to light yellow, free of particles
EVENITY Side Effects: What to Monitor
Monitor patients for both common and serious events.
Common (≥5%):
- Arthralgia
- Headache
Serious:
- Cardiovascular: MI, stroke, cardiovascular death—hazard ratio 1.87 vs alendronate
- Hypocalcemia: Especially in renal impairment; correct before starting
- ONJ and atypical femoral fractures: Evaluate dental health and thigh/groin pain
- Hypersensitivity: Angioedema, rash, urticaria—discontinue if reaction occurs
Key Practitioner Questions About EVENITY Answered
How long can EVENITY be used?
- 12 months max. Afterward, transition to an antiresorptive agent.
Is it effective alone?
- Yes, but follow-up with denosumab or alendronate sustains BMD gains.
Can patients self-inject?
- No. Must be administered by a licensed provider.
Is it safe in renal impairment?
- No dose adjustment needed, but monitor calcium in severe impairment or dialysis.
What happens after stopping?
- Without follow-up treatment, BMD returns to baseline within 12 months
How to Order EVENITY for Your Practice
EVENITY is a prescription biologic available via licensed distributors for in-clinic administration.
Contact Doctor Medica’s customer service representatives for guidance on how to order Evenity online.